Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Fazekas, F; Bajenaru, O; Berger, T; Fabjan, TH; Ledinek, AH; Jakab, G; Komoly, S; Kobys, T; Kraus, J; Kurča, E; Kyriakides, T; Lisý, L; Milanov, I; Nehrych, T; Moskovko, S; Panayiotou, P; Jazbec, SŠ; Sokolova, L; Taláb, R; Traykov, L; Turčáni, P; Vass, K; Vella, N; Voloshyná, N; Havrdová, E.
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Front Neurol. 2013; 4(2):10-10 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Fazekas Franz
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 12
| | | | | | | | | | | |
Abstract:
Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease-modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatment and highly active MS are more effective, they are associated with potentially severe side effects. Fingolimod (Gilenya(®)) is the first oral treatment of MS and has recently been approved as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite basic treatment (beta-interferon) and for treatment-naïve patients with rapidly evolving severe RRMS. At a scientific meeting that took place in Vienna on November 18th, 2011, experts from ten Central and Eastern European countries discussed the clinical benefits and potential risks of fingolimod for MS, suggested how the new therapy fits within the current treatment algorithm and provided expert opinion for the selection and management of patients.

Find related publications in this database (Keywords)
multiple sclerosis
fingolimod
treatment
algorithm
expert opinion
© Meduni Graz Impressum